ObjectiveSodium-glucose cotransporter-2 inhibitors have been identified profound renal/cardiac protective effects in different diseases. Here, we assessed the safety and efficacy of dapagliflozin among adult patients with systemic lupus erythematosus (SLE).MethodsWe conducted a single-arm, open-label, investigator-initiated phase I/II trial of dapagliflozin in Chinese patients with SLE with/without lupus nephritis (LN). Patients received oral dapagliflozin at a daily dose of 10 mg added to the standard of care for 6 months. The primary end point was the safety profile. The secondary efficacy end points were composite assessments of disease activity.ResultsA total of 38 eligible patients were enrolled. Overall, 19 (50%) adverse events (AEs) were recorded, including 8 (21%) AEs leading to drug discontinuation, of which 4 (10.5%) were attributed to dapagliflozin. Two serious AEs (one of major lupus flare and one of fungal pneumonia) were recorded. Lower urinary tract infection was observed in one (2.63%) patient. The secondary end points revealed no improvement of SLE Disease Activity Index scores or proteinuria (among 17 patients with LN); the cumulative lupus flare rate was 18%, and a reduction of ~30% in the prednisone dose was captured. Net changes in body mass index (−0.50 kg/m2), systolic blood pressure (−3.94 mm Hg) and haemoglobin levels (+8.26 g/L) were detected. The overall estimated glomerular filtration rate (eGFR) was stable, and there was an improvement in the eGFR slope among patients with LN with a baseline eGFR <90 mL/min/1.73 m2.ConclusionDapagliflozin had an acceptable safety profile in adult patients with SLE. Its possible renal/cardiac protective effects and long-term safety issues in patients with SLE, patients with LN in particular, call for further exploration.Trial registration numberChiCTR1800015030.
The formation of osteophytes in general is attributed to aging, mechanical stress and local inflammation; however, the precise pathophysiology remains to be clarified. [1][2][3] In ankylosing spondylitis (AS), osteophytes develop in the enthesis at the annulus bone junction of the vertebral body and eventually bridge the adjacent vertebrae, namely syndesmophytes, which are the hallmarks of the disease. 1,[3][4][5] A well-conceived intriguing observation is that osteophytes or syndesmophytes tend to spare the aorta side, as characterized in a non-inflammatory disease, diffuse idiopathic skeletal hyperostosis (DISH), with prominent continuous right-sided syndesmophytes away from aorta (left-sided). 6 In a recent report using a semiautomated method based on computed tomography (CT) scans, Tan et al illustrated that in AS, syndesmophytes are also less frequent and smaller in the area of the vertebral rim adjacent to the aorta than in neighboring regions in the lower thoracic and upper lumbar
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.